全文获取类型
收费全文 | 1138727篇 |
免费 | 83397篇 |
国内免费 | 2634篇 |
专业分类
耳鼻咽喉 | 16365篇 |
儿科学 | 32647篇 |
妇产科学 | 31023篇 |
基础医学 | 162816篇 |
口腔科学 | 33362篇 |
临床医学 | 97097篇 |
内科学 | 227415篇 |
皮肤病学 | 24148篇 |
神经病学 | 94632篇 |
特种医学 | 43239篇 |
外国民族医学 | 271篇 |
外科学 | 171389篇 |
综合类 | 25682篇 |
现状与发展 | 2篇 |
一般理论 | 330篇 |
预防医学 | 90993篇 |
眼科学 | 25697篇 |
药学 | 83544篇 |
中国医学 | 2497篇 |
肿瘤学 | 61609篇 |
出版年
2021年 | 10158篇 |
2019年 | 10371篇 |
2018年 | 16259篇 |
2017年 | 11682篇 |
2016年 | 12558篇 |
2015年 | 14558篇 |
2014年 | 18768篇 |
2013年 | 28448篇 |
2012年 | 42221篇 |
2011年 | 43403篇 |
2010年 | 23832篇 |
2009年 | 20804篇 |
2008年 | 39120篇 |
2007年 | 42182篇 |
2006年 | 40675篇 |
2005年 | 40037篇 |
2004年 | 38462篇 |
2003年 | 36289篇 |
2002年 | 34520篇 |
2001年 | 42141篇 |
2000年 | 42797篇 |
1999年 | 36590篇 |
1998年 | 10470篇 |
1997年 | 9610篇 |
1996年 | 9439篇 |
1995年 | 8917篇 |
1992年 | 29893篇 |
1991年 | 29004篇 |
1990年 | 28378篇 |
1989年 | 27192篇 |
1988年 | 25606篇 |
1987年 | 25065篇 |
1986年 | 23854篇 |
1985年 | 22995篇 |
1984年 | 17819篇 |
1983年 | 15222篇 |
1982年 | 9587篇 |
1979年 | 17949篇 |
1978年 | 12975篇 |
1977年 | 10980篇 |
1976年 | 9979篇 |
1975年 | 10951篇 |
1974年 | 13611篇 |
1973年 | 13130篇 |
1972年 | 12456篇 |
1971年 | 11598篇 |
1970年 | 11060篇 |
1969年 | 10791篇 |
1968年 | 9699篇 |
1967年 | 8880篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
81.
Giorgio Gandaglia Guillaume Ploussard Massimo Valerio Agostino Mattei Cristian Fiori Nicola Fossati Armando Stabile Jean-Baptiste Beauval Bernard Malavaud Mathieu Roumiguié Daniele Robesti Paolo Dell’Oglio Marco Moschini Stefania Zamboni Arnas Rakauskas Francesco De Cobelli Francesco Porpiglia Francesco Montorsi Alberto Briganti 《European urology》2019,75(3):506-514
Background
Available models for predicting lymph node invasion (LNI) in prostate cancer (PCa) patients undergoing radical prostatectomy (RP) might not be applicable to men diagnosed via magnetic resonance imaging (MRI)-targeted biopsies.Objective
To assess the accuracy of available tools to predict LNI and to develop a novel model for men diagnosed via MRI-targeted biopsies.Design, setting, and participants
A total of 497 patients diagnosed via MRI-targeted biopsies and treated with RP and extended pelvic lymph node dissection (ePLND) at five institutions were retrospectively identified.Outcome measurements and statistical analyses
Three available models predicting LNI were evaluated using the area under the receiver operating characteristic curve (AUC), calibration plots, and decision curve analyses. A nomogram predicting LNI was developed and internally validated.Results and limitations
Overall, 62 patients (12.5%) had LNI. The median number of nodes removed was 15. The AUC for the Briganti 2012, Briganti 2017, and MSKCC nomograms was 82%, 82%, and 81%, respectively, and their calibration characteristics were suboptimal. A model including PSA, clinical stage and maximum diameter of the index lesion on multiparametric MRI (mpMRI), grade group on targeted biopsy, and the presence of clinically significant PCa on concomitant systematic biopsy had an AUC of 86% and represented the basis for a coefficient-based nomogram. This tool exhibited a higher AUC and higher net benefit compared to available models developed using standard biopsies. Using a cutoff of 7%, 244 ePLNDs (57%) would be spared and a lower number of LNIs would be missed compared to available nomograms (1.6% vs 4.6% vs 4.5% vs 4.2% for the new nomogram vs Briganti 2012 vs Briganti 2017 vs MSKCC).Conclusions
Available models predicting LNI are characterized by suboptimal accuracy and clinical net benefit for patients diagnosed via MRI-targeted biopsies. A novel nomogram including mpMRI and MRI-targeted biopsy data should be used to identify candidates for ePLND in this setting.Patient summary
We developed the first nomogram to predict lymph node invasion (LNI) in prostate cancer patients diagnosed via magnetic resonance imaging-targeted biopsy undergoing radical prostatectomy. Adoption of this model to identify candidates for extended pelvic lymph node dissection could avoid up to 60% of these procedures at the cost of missing only 1.6% patients with LNI. 相似文献82.
Renaud Snanoudj Nassim Kamar Elisabeth Cassuto Sophie Caillard Marie Metzger Pierre Merville Antoine Thierry Isabelle Jollet Philippe Grimbert Dany Anglicheau Marc Hazzan Gabriel Choukroun Bruno Hurault De Ligny Bénedicte Janbon Vincent Vuiblet Anne Devys Yann Le Meur Michel Delahousse Jean-Luc Taupin 《Kidney international》2019,95(6):1471-1485
83.
Julie A. Schmidt Georgina K. Fensom Sabina Rinaldi Augustin Scalbert Paul N. Appleby David Achaintre Audrey Gicquiau Marc J. Gunter Pietro Ferrari Rudolf Kaaks Tilman Kühn Heiner Boeing Antonia Trichopoulou Anna Karakatsani Eleni Peppa Domenico Palli Sabina Sieri Rosario Tumino Bas Bueno-de-Mesquita Antonio Agudo Maria-Jose Sánchez María-Dolores Chirlaque Eva Ardanaz Nerea Larrañaga Aurora Perez-Cornago Nada Assi Elio Riboli Konstantinos K. Tsilidis Timothy J. Key Ruth C. Travis 《International journal of cancer. Journal international du cancer》2020,146(3):720-730
Metabolomics may reveal novel insights into the etiology of prostate cancer, for which few risk factors are established. We investigated the association between patterns in baseline plasma metabolite profile and subsequent prostate cancer risk, using data from 3,057 matched case–control sets from the European Prospective Investigation into Cancer and Nutrition (EPIC). We measured 119 metabolite concentrations in plasma samples, collected on average 9.4 years before diagnosis, by mass spectrometry (AbsoluteIDQ p180 Kit, Biocrates Life Sciences AG). Metabolite patterns were identified using treelet transform, a statistical method for identification of groups of correlated metabolites. Associations of metabolite patterns with prostate cancer risk (OR1SD) were estimated by conditional logistic regression. Supplementary analyses were conducted for metabolite patterns derived using principal component analysis and for individual metabolites. Men with metabolite profiles characterized by higher concentrations of either phosphatidylcholines or hydroxysphingomyelins (OR1SD = 0.77, 95% confidence interval 0.66–0.89), acylcarnitines C18:1 and C18:2, glutamate, ornithine and taurine (OR1SD = 0.72, 0.57–0.90), or lysophosphatidylcholines (OR1SD = 0.81, 0.69–0.95) had lower risk of advanced stage prostate cancer at diagnosis, with no evidence of heterogeneity by follow-up time. Similar associations were observed for the two former patterns with aggressive disease risk (the more aggressive subset of advanced stage), while the latter pattern was inversely related to risk of prostate cancer death (OR1SD = 0.77, 0.61–0.96). No associations were observed for prostate cancer overall or less aggressive tumor subtypes. In conclusion, metabolite patterns may be related to lower risk of more aggressive prostate tumors and prostate cancer death, and might be relevant to etiology of advanced stage prostate cancer. 相似文献
84.
85.
86.
87.
88.
89.